Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ION251 in relapsed/refractory multiple myeloma
NCT04398485Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jan 2021
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-IRF4 ASO in multiple myeloma (MM), sponsored by Ionis Pharmaceuticals. Primary endpoints: Maximum-Tolerated Dose at Cycle 1 and Recommended Phase 2 Dose. Started Jan 2021; status: completed.
02
Drugs
anti-IRF4 ASO
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04398485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04398485.